Mendel Money Management Purchases New Shares in Certara, Inc. (NASDAQ:CERT)

Mendel Money Management acquired a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,700 shares of the company's stock, valued at approximately $519,000.

Several other large investors have also bought and sold shares of CERT. Summitry LLC acquired a new stake in shares of Certara in the fourth quarter valued at about $124,000. Zions Bancorporation N.A. boosted its holdings in Certara by 14.6% in the fourth quarter. Zions Bancorporation N.A. now owns 87,992 shares of the company's stock valued at $937,000 after acquiring an additional 11,181 shares during the last quarter. Vanguard Group Inc. increased its position in Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock valued at $132,455,000 after purchasing an additional 38,068 shares during the period. LPL Financial LLC raised its holdings in Certara by 17.3% during the 4th quarter. LPL Financial LLC now owns 112,624 shares of the company's stock worth $1,288,000 after purchasing an additional 16,586 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Certara in the 4th quarter worth approximately $276,000. 73.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Barclays lifted their target price on shares of Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. William Blair reissued a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Finally, TD Cowen initiated coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.83.

Remove Ads

Certara Stock Down 2.1 %

Certara stock traded down $0.21 during midday trading on Friday, reaching $9.91. The stock had a trading volume of 957,466 shares, compared to its average volume of 1,036,251. The company has a fifty day moving average price of $12.43 and a two-hundred day moving average price of $11.45. The company has a market capitalization of $1.60 billion, a P/E ratio of -49.55, a PEG ratio of 9.29 and a beta of 1.60. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.18.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.